NEURALINK 2025: - Received FDA Breakthrough Device Designation for its speech restoration technology targeting severe speech impairments. - Launched its first clinical trial in the Middle East (UAE-PRIME) at Cleveland Clinic Abu Dhabi in partnership with the Department of Health Abu Dhabi. - Raised $650 million in Series E funding, led by investors including ARK Invest, Sequoia Capital, and Founders Fund, valuing the company at approximately $9 billion. - Launched clinical trials in the United Kingdom in partnership with University College London Hospitals and Newcastle Hospitals. - Performed its first procedures outside the United States, implanting devices in two patients with cervical spinal cord injuries at Toronto's University Health Network in Canada. - Completed two surgeries in Canada, marking the first non-US procedures. - The first UK participant, Paul, received an implant and controlled a computer with thoughts hours after surgery at University College London Hospitals. - Convoy project testing with participants controlling robotic arms with their BCIs. - Introduced an upgraded next-generation surgical robot with improved electrode thread insertion time of 1.5 seconds per thread, greater insertion depths over 50mm, enhances compatibility with 99% of anatomical variations globally, and lowers manufacturing costs for needle cartridges by 95%. - Announced goals for faster LASIK-like implant procedures in minutes and emphasized flexible electrode threads for safer neuron placement. - As of now it is estimated that Neuralink as 20 participants. Know are Noland Arbaugh (@ModdedQuad), Alex Conley (@Bcidesign), Bradford Smith (@ALScyborg), Michael Melgarejo, RJ Tanner, Rob Greiner (@greiner_ro52817), Jake Schneider (@PairedWith_P7), Nick Wray (@Telepath_8), Audrey Crews (@NeuraNova9), Paul, and Jon L. Noble (@CheckCanopy).